Adipocytes, aldosterone and obesity-related hypertension

Journal of Molecular Endocrinology

Volumn 57, Issue 1, 2016, Pages F7-F21

  Cat, Aurelie Nguyen Dinh ^a   Friederich Persson, Malou ^a   White, Anna ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adipocytes; Aldosterone; Obesity related hypertension; Synthesis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALDOSTERONE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COMPLEMENT C1Q TNF RELATED PROTEIN 1; COMPLEMENT COMPONENT C1Q; EPLERENONE; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADIPOCYTE; ADIPOSE TISSUE; ADRENAL GLAND; ADRENAL GLAND TISSUE; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; EXPERIMENTAL STUDY; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNTHESIS; WEIGHT REDUCTION; ANIMAL; ANTIBODY SPECIFICITY; COMPLICATION; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADRENAL GLANDS; ALDOSTERONE; ANIMALS; BIOMARKERS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; OBESITY; ORGAN SPECIFICITY; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84976613345     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-16-0025     Document Type: Review

References (145)

1. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E & Flier JS 1996 Role of leptin in the neuroendocrine response to fasting. Nature 382 250-252. (doi:10.1038/382250a0)
2. Ahima RS 2008 Revisiting leptin's role in obesity and weight loss. Journal of Clinical Investigation 118 2380-2383. (doi:10.1172/JCI36284)
3. Amar L, Azizi M, Menard J, Peyrard S, Watson C & Plouin PF 2010 Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56 831-838. (doi:10.1161/HYPERTENSIONAHA.110.157271)
4. Antoniades C, Antonopoulos AS, Tousoulis D & Stefanadis C 2009 Adiponectin: from obesity to cardiovascular disease. Obesity Reviews 10 269-279. (doi:10.1111/j.1467-789X.2009.00571.x.)
5. Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L, Sanna F, De Silva R, Petrou M, Sayeed R, et al. 2015 Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 64 2207-2219. (doi:10.2337/ db14-1011)
6. Arakane F, King SR, Du Y, Kallen CB, Walsh LP, Watari H, Stocco DM & Strauss JF 3rd 1997 Phosphorylation of steroidogenic acute regulatory protein (StAR) modulates its steroidogenic activity. Journal of Biological Chemistry 272 32656-32662. (doi:10.1074/ jbc.272.51.32656)
7. Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, Carpinelli G, Canese R, Pagotto U, Quarta C, et al. 2014 Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB Journal 28 3745-3757. (doi:10.1096/fj.13-245415)
8. Balland E & Cowley MA 2015 New insights in leptin resistance mechanisms in mice. Frontiers in Neuroendocrinology 39 59-65. (doi:10.1016/j.yfrne.2015.09.004)
9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357 2109-2122. (doi:10.1056/NEJMoa0706628)
10. Bassett MH, Zhang Y, White PC & Rainey WE 2000 Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element. Endocrine Research 26 941-951. (doi:10.3109/07435800009048620)
11. Bassett MH, White PC & Rainey WE 2004 The regulation of aldosterone synthase expression. Molecular and Cellular Endocrinology 217 67-74. (doi:10.1016/j.mce.2003.10.011)
12. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH & Garg R 2007 Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. Journal of Clinical Endocrinology and Metabolism 92 4472-4475. (doi:10.1210/jc.2007-1088)
13. Bird IM, Hanley NA, Word RA, Mathis JM, McCarthy JL, Mason JI & Rainey WE 1993 Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 133 1555-1561. (doi:10.1210/endo.133.4.8404594)
14. Bird IM, Mathis JM, Mason JI & Rainey WE 1995 Ca(2+)-regulated expression of steroid hydroxylases in H295R human adrenocortical cells. Endocrinology 136 5677-5684. (doi:10.1210/ endo.136.12.7588323)
15. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C & Burnier M 2006 Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 239-245. (doi:10.1161/01.HYP.0000231338.41548.fc)
16. Bollag WB 2014 Regulation of aldosterone synthesis and secretion. Comprehensive Physiology 4 1017-1055. (doi:10.1002/cphy.c130037)
17. Bomback AS, Muskala P, Bald E, Chwatko G & Nowicki M 2009 Lowdose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clinical Nephrology 72 449-456. (doi:10.5414/CNP72449)
18. Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, Facchetti R, Redon J, Mancia G & Grassi G 2013 Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. Journal of Hypertension 31 2018-2024. (doi:10.1097/HJH.0b013e328363823f)
19. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, et al. 2012 Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59 1069-1078. (doi:10.1161/HYPERTENSIONAHA.111.190223)
20. Bruder-Nascimento T, da Silva MA & Tostes RC 2014 The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetology and Metabolic Syndrome 6 90. (doi:10.1186/1758-5996-6-90)
21. Calhoun DA & Sharma K 2010 The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiology Clinics 28 517-527. (doi:10.1016/j.ccl.2010.04.001)
22. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP & Ménard J 2011 Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial. Circulation 124 1945-1955. (doi:10.1161/ CIRCULATIONAHA.111.029892)
23. Campbell JE, Peckett AJ, D'souza AM, Hawke TJ & Riddell MC 2011 Adipogenic and lipolytic effects of chronic glucocorticoid exposure. American Journal of Physiology Cell Physiology 300 C198-209. (doi:10.1152/ajpcell.00045.2010)
24. Caprio M, Fève B, Claës A, Viengchareun S, Lombès M & Zennaro MC 2007 Pivotal role of the mineralocorticoid receptor in corticosteroidinduced adipogenesis. FASEB Journal 21 2185-2194. (doi:10.1096/ fj.06-7970com)
25. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, Fabbri A, Zennaro MC & Fève B 2011 Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 152 113-125. (doi:10.1210/en.2010-0674)
26. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A & Sechi LA 2006 Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Journal of Clinical Endocrinology and Metabolism 91 3457-3463. (doi:10.1210/ jc.2006-0736)
27. Chalupova L, Zakovska A & Adamcova K 2013 Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. Clinical Biochemistry 46 73-78. (doi:10.1016/j.clinbiochem.2012.09.006)
28. Chen M, Wang Z, Zhan M, Liu R, Nie A, Wang J, Ning G & Ma Q 2014 Adiponectin regulates ACTH secretion and the HPAA in an AMPKdependent manner in pituitary corticotroph cells. Molecular and Cellular Endocrinology 383 118-125. (doi:10.1016/j.mce.2013.12.007)
29. Crujeiras AB, Carreira MC, Cabia B, Andrade S, Amil M & Casanueva FF 2015 Leptin resistance in obesity: An epigenetic landscape. Life Science 140 57-63. (doi:10.1016/j.lfs.2015.05.003)
30. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R & Considine RV 2005 Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obesity Research 13 662-669. (doi:10.1038/oby.2005.74)
31. Delcayre C & Silvestre JS 1999 Aldosterone and the heart: towards a physiological function? Cardiovascular Research 43 7-12. (doi:10.1016/S0008-6363(99)00088-7)
32. Denner K, Rainey WE, Pezzi V, Bird IM, Bernhardt R & Mathis JM 1996 Differential regulation of 11 beta-hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Molecular and Cellular Endocrinology 121 87-91. (doi:10.1016/0303-7207(96)03853-1)
33. de Paula RB, da Silva AA & Hall JE 2004 Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43 41-47. (doi:10.1161/01. HYP.0000105624.68174.00)
34. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER & Monder C 1988 Localisation of 11 betahydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet 2 986-989.
35. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA & Bornstein SR 2003 Human adipocytes secrete mineralocorticoidreleasing factors. PNAS 100 14211-14216. (doi:10.1073/ pnas.2336140100)
36. Felizola SJ, Maekawa T, Nakamura Y, Satoh F, Ono Y, Kikuchi K, Aritomi S, Ikeda K, Yoshimura M, Tojo K, et al. 2014 Voltage-gated calcium channels in the human adrenal and primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology 144 410-416. (doi:10.1016/j.jsbmb.2014.08.012)
37. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, et al. 2005 Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111 3087-3094. (doi:10.1161/ CIRCULATIONAHA.104.521625)
38. Freitas Lima LC, Braga VA, do Socorro de França Silva M, Cruz JC, Sousa Santos SH, de Oliveira Monteiro MM & Balarini CM 2015 Adipokines, diabetes and atherosclerosis: an inflammatory association. Frontiers in Physiology 6 304. (doi:10.3389/ fphys.2015.00304)
39. Friedman J 2014 20 years of leptin: leptin at 20: an overview. Journal of Endocrinology 223 T1-T8. (doi:10.1530/JOE-14-0405)
40. Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, Ikeda H, Wada Y, Sasano H & Koshiyama H 2013 Primary aldosteronism associated with subclinical Cushing syndrome. Journal of Endocrinological Investigation 36 564-567. (doi:10.3275/8818)
41. Funder JW 2005 Mineralocorticoid receptors: distribution and activation. Heart Failure Review 10 15-22. (doi:10.1007/s10741-005-2344-2)
42. Furukawa A, Miyatake A, Ohnishi T & Ichikawa Y 1998 Steroidogenic acute regulatory protein (StAR) transcripts constitutively expressed in the adult rat central nervous system: colocalization of StAR, cytochrome P-450SCC (CYP XIA1), and 3beta-hydroxysteroid dehydrogenase in the rat brain. Journal of Neurochemistry 71 2231-2238.
43. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M & Shimomura I 2004 Increased oxidative stress in obesity and its impact on metabolic syndrome. Journal of Clinical Investigation 114 1752-1761. (doi:10.1172/JCI21625)
44. Gamliel-Lazarovich A, Raz-Pasteur A, Coleman R & Keidar S 2013 The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. European Journal of Gastroenterology and Hepatology 25 1086-1092. (doi:10.1097/MEG.0b013e328360554a)
45. Garg R, Hurwitz S, Williams GH, Hopkins PN & Adler GK 2010 Aldosterone production and insulin resistance in healthy adults. Journal of Clinical Endocrinology and Metabolism 95 1986-1990. (doi:10.1210/jc.2009-2521)
46. Gauthier MS, O'Brien EL, Bigornia S, Mott M, Cacicedo JM, Xu XJ, Gokce N, Apovian C & Ruderman N 2011 Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochemical and Biophysical Research Communications 404 382-387. (doi:10.1016/j.bbrc.2010.11.127)
47. Gilbert KC & Brown NJ 2010 Aldosterone and inflammation. Current Opinion in Endocrinology, Diabetes Obesity 17 199-204.
48. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Eddleman FC & Gomez-Sanchez EP 1996 Corticosteroid synthesis in the central nervous system. Endocrine Research 22 463-470. (doi:10.1080/07435809609043732)
49. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF & Gomez-Sanchez EP 1997 Aldosterone biosynthesis in the rat brain. Endocrinology 138 3369-3373. (doi:10.1210/endo.138.8.5326#sthash. fA0p6z5p.dpuf)
50. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, Krishnaswami S, Pausova Z, Roman R, Tremblay J, et al. 2005 Hyperaldosteronism and hypertension: ethnic differences. Hypertension 45 766-772. (doi:10.1161/01.HYP.0000154364.00763.d5)
51. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH & Adler GK 2008 Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117 2253-2261. (doi:10.1161/CIRCULATIONAHA.107.748640)
52. Hall JE, do Carmo JM, da Silva AA, Wang Z & Hall ME 2015 Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation Research 116 991-1006. (doi:10.1161/ CIRCRESAHA.116.305697)
53. Hargovan M & Ferro A 2014 Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovascular Disease 3 2048004014522440. (doi:10.1177/2048004014522440. eCollection 2014)
54. Hatakeyama H, Miyamori I, Takeda Y, Yamamoto H & Mabuchi H 1996 The expression of steroidogenic enzyme genes in human vascular cells. Biochemistry and Molecular Biology International Journal 40 639-645.
55. Hattangady NG, Olala LO, Bollag WB & Rainey WE 2012 Acute and chronic regulation of aldosterone production. Molecular and Cellular Endocrinology 350 151-162. (doi:10.1016/j.mce.2011.07.034)
56. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T & Shimomura I 2009 Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research 84 164-172. (doi:10.1093/cvr/ cvp191)
57. Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T & Shimomura I 2012 Contribution of glucocorticoidmineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochemical and Biophysical Research Communications 419 182-187. (doi:10.1016/j.bbrc.2012.01.139)
58. Hirsch A, Hahn D, Kempná P, Hofer G, Mullis PE, Nuoffer JM & Flück CE 2012 Role of AMP-activated protein kinase on steroid hormone biosynthesis in adrenal NCI-H295R cells. PLoS ONE 7 e30956. (doi:10.1371/journal.pone.0030956)
59. Hosoya K, Minakuchi H, Wakino S, Fujimura K, Hasegawa K, Komatsu M, Yoshifuji A, Futatsugi K, Shinozuka K, Washida N, et al. 2015 Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney International 87 749-760. (doi:10.1038/ki.2014.348)
60. Hou N & Luo JD 2011 Leptin and cardiovascular diseases. Clinical and Experimental Pharmacology and Physiology 38 905-913. (doi:10.1111/j.1440-1681.2011.05619.x)
61. Hu C, Rusin CG, Tan Z, Guagliardo NA & Barrett PQ 2012 Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. Journal of Clinical Investigation 122 2046-2053. (doi:10.1172/JCI61996)
62. Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA & Belin de Chantemèle EJ 2015 Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132 2134-2145. (doi:10.1161/ CIRCULATIONAHA.115.018226)
63. Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Segal MS & Christou DD 2013 Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clinical Science 125 513-520. (doi:10.1042/CS20130200)
64. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, Campbell KL, Duggan C, Foster-Schubert KE, Kong A, et al. 2012 Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Research 72 2314-2326. (doi:10.1158/0008-5472.CAN-11-3092)
65. Iwen KA, Senyaman O, Schwartz A, Drenckhan M, Meier B, Hadaschik D & Klein J 2008 Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. Journal of Endocrinology 196 465-472. (doi:10.1677/JOE-07-0299)
66. Jaisser F & Farman N 2016 Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacological Reviews 68 49-75. (doi:10.1124/ pr.115.011106)
67. Jeon JH, Kim KY, Kim JH, Baek A, Cho H, Lee YH, Kim JW, Kim D, Han SH, Lim JS, et al. 2008 A novel adipokine CTRP1 stimulates aldosterone production. FASEB Journal 22 1502-1511. (doi:10.1096/ fj.07-9412com)
68. Johns DG, Duffy J, Fisher T, Hubbard BK & Forrest MJ 2012 On-and offtarget pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 72 491-507. (doi:10.2165/11599310-000000000-00000)
69. Kargi AY & Iacobellis G 2014 Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications. International Journal of Endocrinology 2014 614074. (doi:10.1155/2014/614074)
70. Karns AD, Bral JM, Hartman D, Peppard T & Schumacher C 2013 Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. Journal of Clinical Hypertension 15 186-192. (doi:10.1111/jch.12051)
71. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ & Kotchen TA 2007 Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 704-711. Erratum in: Hypertension 49 e20.
72. Kim KY, Kim HY, Kim JH, Lee CH, Kim DH, Lee YH, Han SH, Lim JS, Cho DH, Lee MS, et al. 2006 Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. FEBS Letters 580 3953-3960. (doi:10.1016/j. febslet.2006.06.034)
73. Kontush A, Guérin M & Chapman MJ 2008 Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nature Clinical Practice Cardiovascular Medicine 5 329-336. (doi:10.1038/ncpcardio1191)
74. Koska J, de Courten B, Wake DJ, Nair S, Walker BR, Bunt JC, Permana PA, Lindsay RS & Tataranni PA 2006 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance. Obesity 14 1515-1522. (doi:10.1038/oby.2006.175)
75. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A & Marwick TH 2013 Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 99 320-326. (doi:10.1136/heartjnl-2012-303329)
76. Krug AW, Vleugels K, Schinner S, Lamounier-Zepter V, Ziegler CG, Bornstein SR & Ehrhart-Bornstein M 2007 Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. International Journal of Obesity 31 1605-1616. (doi:10.1038/sj.ijo.0803642)
77. Krug AW & Ehrhart-Bornstein M 2008 Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51 1252-1258. (doi:10.1161/ HYPERTENSIONAHA.107.109439)
78. Kushida A & Tamura H 2009 Retinoic acids induce neurosteroid biosynthesis in human glial GI-1 Cells via the induction of steroidogenic genes. Journal of Biochemistry 146 917-923. (doi:10.1093/jb/mvp142)
79. Le Goascogne C, Robel P, Gouézou M, Sananès N, Baulieu EE & Waterman M 1987 Neurosteroids: cytochrome P-450scc in rat brain. Science 237 1212-1215. (doi:10.1126/science.3306919)
80. Li J, Feltzer RE, Dawson KL, Hudson EA & Clark BJ 2003 Janus kinase 2 and calcium are required for angiotensin II-dependent activation of steroidogenic acute regulatory protein transcription in H295R human adrenocortical cells. Journal of Biological Chemistry 278 52355-52362. (doi:10.1074/jbc.M305232200)
81. Li P, Sun F, Cao HM, Ma QY, Pan CM, Ma JH, Zhang XN, Jiang H, Song HD & Chen MD 2009 Expression of adiponectin receptors in mouse adrenal glands and the adrenocortical Y-1 cell line: adiponectin regulates steroidogenesis. Biochemical and Biophysical Research Communications 390 1208-1213. (doi:10.1016/j. bbrc.2009.10.122)
82. Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, Rogol A & Miller WL 1995 Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267 1828-1831. (doi:10.1126/science.7892608)
83. Luo P, Dematteo A, Wang Z, Zhu L, Wang A, Kim HS, Pozzi A, Stafford JM & Luther JM 2013 Aldosterone deficiency prevents highfat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 56 901-910. (doi:10.1007/s00125-012-2814-8)
84. Mantzoros CS 1999 The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine 130 671-680. (doi:10.7326/0003-4819-130-8-199904200-00014)
85. Marcinko K & Steinberg GR 2014 The role of AMPK in controlling metabolism and mitochondrial biogenesis during exercise. Experimental Physiology 99 1581-1585. (doi:10.1113/ expphysiol.2014.082255)
86. Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A, Rosano GM & Caprio M 2012 The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Molecular Cellular and Endocrinology 350 281-288. (doi:10.1016/j.mce.2011.09.011)
87. Matsumoto S, Takebayashi K & Aso Y 2006 The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 55 1645-1652. (doi:10.1016/j.metabol.2006.07.025)
88. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, et al. 2012 Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature Medicine 8 1429-1433. (doi:10.1038/nm.2891)
89. Ménard J & Pascoe L 2006 Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosteronesynthase inhibition? Journal of Hypertension 24 993-997. (doi:10.1097/01.hjh.0000226183.98439.b3)
90. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ & Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 931-938. (doi:10.2337/diabetes.53.4.931)
91. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K & Fujita T 2006 Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. Journal of the American Society of Nephrology 17 3438-3446. (doi:10.1681/ASN.2006080944)
92. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D & Jaisser F 2010 The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB Journal 24 2454-2463. (doi:10.1096/fj.09-147926)
93. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC & Touyz RM 2011 Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 58 479-488. (doi:10.1161/ HYPERTENSIONAHA.110.168872)
94. Nguyen Dinh Cat A & Jaisser F 2012 Extrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension 21 147-156. (doi:10.1097/MNH.0b013e32834fb25b)
95. Nguyen Dinh Cat A, Antunes TT, Callera GE, Sanchez A, Tsiropoulou S, Dulak-Lis MG, Anagnostopoulou A, He Y, Montezano AC, Jaisser F & Touyz RM 2016 Adipocytes-specific mineralocorticoid receptors overexpression in mice is associated with metabolic syndrome and vascular dysfunction: role of redox-sensitive PKG-1 and Rho kinase. Diabetes [in press]. (doi:10.2337/db15-1627)
96. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A & Daniele A 2014 New insight into adiponectin role in obesity and obesity-related diseases. Biomed Research International 2014 658913. (doi:10.1155/2014/658913)
97. Northcott CA, Fink GD, Garver H, Haywood JR, Laimon-Thomson EL, McClain JL, Pires PW, Rainey WE, Rigsby CS & Dorrance AM 2012 The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity. Endocrinology 153 1764-1773. (doi:10.1210/en.2011-1176)
98. O'Keefe JH, Abuissa H & Pitt B 2008 Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes, Obesity and Metabolism 10 492-497. (doi:10.1111/j.1463-1326.2007.00730.x)
99. Pan H, Guo J & Su Z 2014 Advances in understanding the interrelations between leptin resistance and obesity. Physiology and Behavior 130 157-169. (doi:10.1016/j.physbeh.2014.04.003)
100. Park HK & Ahima RS 2014 Leptin signaling. F1000Prime Reports 6 73. (doi:10.12703/P6-73. eCollection 2014)
101. Park HK & Ahima RS 2015 Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism 6 24-34. (doi:10.1016/j.metabol.2014.08.004)
102. Paschke L, Zemleduch T, Rucinski M, Ziolkowska A, Szyszka M & Malendowicz LK 2010 Adiponectin and adiponectin receptor system in the rat adrenal gland: ontogenetic and physiologic regulation, and its involvement in regulating adrenocortical growth and steroidogenesis. Peptides 31 1715-1724. (doi:10.1016/j.peptides.2010.06.007)
103. Peterson JM, Aja S, Wei Z & Wong GW 2012 CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. Journal of Biological Chemistry 287 1576-1587. (doi:10.1074/jbc.M111.27833)
104. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 341 709-717. (doi:10.1056/NEJM199909023411001)
105. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J & Gatlin M 2003 Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348 1309-1321. Erratum in: New England Journal of Medicine 348 2271. (doi:10.1056/NEJMoa030207)
106. Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Zannad F, et al. 2012 Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure 14 909-915. (doi:10.1093/eurjhf/hfs067)
107. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R & Mason JI 1993 Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. Journal of Clinical Endocrinology and Metabolism 77 731-737. (doi:10.1210/ jcem.77.3.8396576)
108. Rajamohan SB, Raghuraman G, Prabhakar NR & Kumar GK 2012 NADPH oxidase-derived H(2)O(2) contributes to angiotensin II-induced aldosterone synthesis in human and rat adrenal cortical cells. Antioxidants and Redox Signaling 17 445-459. (doi:10.1089/ ars.2011.4176)
109. Rios FJ, Neves KB, Nguyen Dinh Cat A, Even S, Palacios R, Montezano AC & Touyz RM 2015 Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. Journal of Pharmacology and Experimental Therapeutics 353 27-34. (doi:10.1124/jpet.114.221002)
110. Romero DG, Plonczynski M, Vergara GR, Gomez-Sanchez EP & Gomez-Sanchez CE 2004 Angiotensin II early regulated genes in H295R human adrenocortical cells. Physiological Genomics 19 106-116. (doi:10.1152/physiolgenomics.00097.2004)
111. Rossi GP, Sticchi D, Giuliani L, Bernante P, Zavattiero S, Pessina AC & Nussdorfer GG 2006 Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. International Journal of Molecular Medicine 17 975-980. (doi:10.3892/ijmm.17.6.975)
112. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, et al. 2008 Primary aldosteronism prevalence in hypertension study investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. Journal of Clinical Endocrinology and Metabolism 93 2566-2571. (doi:10.1210/jc.2008-0251)
113. Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B & Zannad F 2011 Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Journal of the American College of Cardiology 58 1958-1966. (doi:10.1016/j.jacc.2011.04.049)
114. Sainte-Marie Y, Nguyen Dinh Cat A, Perrier R, Mangin L, Soukaseum C, Peuchmaur M, Tronche F, Farman N, Escoubet B, Benitah JP, et al. 2007 Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB Journal 21 3133-3141. (doi:10.1096/fj.07-8357com)
115. Sáinz N, Barrenetxe J, Moreno-Aliaga MJ & Martínez JA 2015 Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 64 35-46. (doi:10.1016/j.metabol.2014.10.015)
116. Schäfer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Lüscher TF, et al. 2013 Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. European Heart Journal 34 3515-3524. (doi:10.1093/eurheartj/eht095)
117. Schinner S, Willenberg HS, Krause D, Schott M, Lamounier-Zepter V, Krug AW, Ehrhart-Bornstein M, Bornstein SR & Scherbaum WA 2007 Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. International Journal of Obesity 31 864-870. (doi:10.1038/sj.ijo.0803508)
118. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, et al. 2012 Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine 367 2089-2099. (doi:10.1056/ NEJMoa1206797)
119. Shibata R, Murohara T & Ouchi N 2012 Protective role of adiponectin in cardiovascular disease. Current Medicinal Chemistry 19 5459-5466. (doi:10.2174/092986712803833164)
120. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B & Delcayre C 1998 Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry 273 4883-4891. (doi:10.1074/ jbc.273.9.4883)
121. Sowers JR 2008 Endocrine functions of adipose tissue: focus on adiponectin. Clinical Cornerstone 9 32-38. (doi:10.1016/S1098-3597(08)60026-5)
122. Sowers JR, Whaley-Connell A & Epstein M 2009 Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 150 776-783. (doi:10.7326/0003-4819-150-11-200906020-00005)
123. Späth M, Korovkin S, Antke C, Anlauf M & Willenberg HS 2011 Aldosterone-and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. European Journal of Endocrinology 164 447-55. (doi:10.1530/EJE-10-1070)
124. Stimson RH & Walker BR 2007 Glucocorticoids and 11betahydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinologica 32 141-159.
125. Strömstedt M & Waterman MR 1995 Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. Brain Research Molecular Brain Research 34 75-88. (doi:10.1016/0169-328X(95)00140-N)
126. Sweeney G 2010 Cardiovascular effects of leptin. Nature Reviews Cardiology 7 22-29. (doi:10.1038/nrcardio.2009.224)
127. Takeda R, Hatakeyama H, Takeda Y, Iki K, Miyamori I, Sheng WP, Yamamoto H & Blair IA 1995 Aldosterone biosynthesis and action in vascular cells. Steroids 60 120-124. Erratum in: Steroids 60 540. (doi:10.1210/jcem.81.8.8768832)
128. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY & Takeda R 1995 Production of aldosterone in isolated rat blood vessels. Hypertension 25 170-173. (doi:10.1161/01.HYP.25.2.170)
129. Takeda Y, Miyamori I, Yoneda T, Furukawa K, Hatakeyama H, Inaba S, Ito Y, Takeda R & Mabuchi H 1996 Effect of adrenocorticotropin stimulation on the synthesis of 19-noraldosterone in man. Journal of Clinical Endocrinology and Metabolism 81 1852-1855. (doi:10.1210/ jcem.81.5.8626846)
130. Thatcher S, Yiannikouris F, Gupte M & Cassis L 2009 The adipose reninangiotensin system: role in cardiovascular disease. Molecular and Cellular Endocrinology 302 111-117. (doi:10.1016/j.mce.2009.01.019)
131. Tirosh A, Garg R, Adler GK 2010 Mineralocorticoid receptor antagonists and the metabolic syndrome. Current Hypertension Reports 12 252-257. (doi:10.1007/s11906-010-0126-2)
132. Tokuyama H, Wakino S, Hara Y, Washida N, Fujimura K, Hosoya K, Yoshioka K, Hasegawa K, Minakuchi H, Homma K, et al. 2012 Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesityrelated renal injury. International Journal of Obesity 36 1062-1071. (doi:10.1038/ijo.2011.232)
133. Urbanet R, Nguyen Dinh Cat A, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C, Alvarez de la Rosa D, Adler GK, Quilliot D, Rossignol P, et al. 2015 Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension 66 149-157. (doi:10.1161/ HYPERTENSIONAHA.114.04981)
134. Vogt B, Bochud M & Burnier M 2007 The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Seminars in Nephrology 27 529-537. (doi:10.1016/j. semnephrol.2007.07.009)
135. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H & Sasaoka T 2009 Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 150 1662-1669. (doi:10.1210/en.2008-1018)
136. Wada N, Hirako S, Takenoya F, Kageyama H, Okabe M & Shioda S 2014 Leptin and its receptors. Journal of Chemical Neuroanatomy 61-62 191-199. (doi:10.1016/j.jchemneu.2014.09.002)
137. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R & Lodish HF 2008 Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissueselective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochemical Journal 416 161-177. (doi:10.1042/ BJ20081240)
138. Wu P, Guo Z, Zhang Y, Liu Y, Liang X, Zhang R, Lai W, Takeda Y, Isamu M & Takeda R 1998 Aldosterone overproduction and CYP11B2 mRNA overexpression in vessels of spontaneously hypertensive rats. Hormone Research 50 28-31. (doi:10.1159/000023197)
139. Xin Y, Lyu X, Wang C, Fu Y, Zhang S, Tian C, Li Q & Zhang D 2014 Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients. Endocrine Journal 61 841-847. (doi:10.1507/endocrj.EJ14-0016)
140. Yamashiro T, Kuge H, Zhang J & Honke K 2010 Calcineurin mediates the angiotensin II-induced aldosterone synthesis in the adrenal glands by up-regulation of transcription of the CYP11B2 gene. Journal of Biochemistry 148 115-123. (doi:10.1093/jb/mvq037)
141. Yang R & Barouch LA 2007 Leptin signaling and obesity: cardiovascular consequences. Circulation Research 101 545-559. (doi:10.1161/ CIRCRESAHA.107.156596)
142. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B & EMPHASIS-HF Study Group 2011 Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine 364 11-21. (doi:10.1056/ NEJMoa1009492)
143. Zennaro MC, Caprio M & Fève B 2009 Mineralocorticoid receptors in the metabolic syndrome. Trends in Endocrinology and Metabolism 20 444-451. (doi:10.1016/j.tem.2009.05.006)
144. Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F & Scaroni C 2005 Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. Journal of Endocrinology Investigation 28 49-53. (doi:10.1007/ BF03345529)
145. Zwain IH & Yen SS 1999 Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 140 3843-3852.